Skip to main content

Anxiety Disorder

Neurology
5
Pipeline Programs
9
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
1
0
Early DiscoveryClinical DevelopmentMarket

Market Intelligence

$26.9B
Market Size
4,186
Active Jobs
15
Companies
8,279
Clinical Trials

The Neurology therapeutic area represents a $26.9B market dominated by anticoagulants and atypical antipsychotics. ELIQUIS (apixaban) is the clear revenue driver at $18.27B, representing 68% of the top 10 products' combined spending. The market is characterized by a mix of mature peak-lifecycle products and newer oral migraine therapies, with most major drugs still under patent protection through the 2030s-2040s.

AI-generated market analysis

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Prevail Therapeutics
1 program
1
DuloxetinePhase 3
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
MK0777Phase 2
MSD
MSDIreland - Ballydine
1 program
1
MK0777Phase 2
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
ParoxetinePhase 2
Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
Cipralex®Phase 11 trial
Active Trials
NCT01293838Unknown30Est. Jan 2012
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
2 programs
a benzodiazepine drugPHASE_31 trial
experimental anti-anxiety drugPHASE_31 trial
Active Trials
NCT00106860Completed158Est. Mar 2006
NCT00097708Completed511Est. Dec 2005
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
DuloxetinePHASE_31 trial
Active Trials
NCT00122837Completed560Est. Jan 2007
Teva
TevaIsrael - Petach Tikva
1 program
GabitrilPHASE_31 trial
Active Trials
NCT00236015Completed880Est. Mar 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer IngelheimDuloxetine
Jazz Pharmaceuticalsa benzodiazepine drug
Jazz Pharmaceuticalsexperimental anti-anxiety drug
TevaGabitril
LundbeckCipralex®

Clinical Trials (5)

Total enrollment: 2,139 patients across 5 trials

NCT00122837Boehringer IngelheimDuloxetine

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Start: Apr 2005Est. completion: Jan 2007560 patients
Phase 3Completed
NCT00106860Jazz Pharmaceuticalsa benzodiazepine drug

A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

Start: Mar 2005Est. completion: Mar 2006158 patients
Phase 3Completed
NCT00097708Jazz Pharmaceuticalsexperimental anti-anxiety drug

Experimental Medication For the Treatment of Generalized Anxiety Disorder

Start: Nov 2004Est. completion: Dec 2005511 patients
Phase 3Completed
NCT00236015TevaGabitril

A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

Start: Nov 2004Est. completion: Mar 2006880 patients
Phase 3Completed
NCT01293838LundbeckCipralex®

Cipralex® for Anxiety Disorders in Adolescents

Start: Mar 2008Est. completion: Jan 201230 patients
Phase 1Unknown

Related Jobs in Neurology

(Starter) Building Automation Engineer

Merck & Co.Merck & Co.
NLD - North Brabant - Boxmeer (Not Applicable)
3d ago

Co-op, Chemistry 2026

ModernaModerna
Cambridge, Massachusetts; Research
3d ago

Automation Engineering, Clinical Biomarker Lab 2026 Intern

ModernaModerna
Norwood, Massachusetts; Clinical Development
3d ago

Technician III, Process/Utility Maintenance

ModernaModerna
Marlborough, Massachusetts; Technical Development
3d ago
$63K - $101K/yr

Senior Servicenow CMDB Technical Lead

ModernaModerna
Cambridge, Massachusetts; Digital
3d ago
$131K - $209K/yr

Scientist, Drug Safety (Fixed Term)

Merck & Co.Merck & Co.
COL - Cundinamarca - Bogotá (Colpatria) (Not Applicable)
3d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

Related Indications

Schizophrenia(643)Multiple Sclerosis(496)Alzheimer's Disease(408)Epilepsy(404)Parkinson Disease(392)Parkinson's Disease(348)Alzheimer Disease(269)Stroke(242)Migraine(235)Depression(198)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.